A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Martin Schrappe, Hanna Marie Gottschalk, Valentino Conter, Gunnar Cario, Jan Stary, Anja Möricke, Michael Dworzak, Andishe Attarbaschi, Draga Barbaric, Franco Locatelli, Nicole Bodmer, Sarah Elitzur, Daniela Silvestri, Luciano Dalla-Pozza, Bernd Gruhn, Shai Izraeli, Carmelo Rizzari, Jean-Pierre Bourquin, Andrea Biondi, Maria Grazia Valsecchi, Martin Zimmermann
Institutions: Christian-Albrechts-Universität zu Kiel, Deutsche Forschungsgemeinschaft, University Hospital Schleswig-Holstein, Charles University, University Hospital in Motol, St Anna Children's Hospital, St. Anna Children's Cancer Research Institute, Medical University of Vienna, UNSW Sydney, Sydney Children's Hospital, Università Cattolica del Sacro Cuore, Bambino Gesù Children's Hospital, University Children's Hospital Zurich, Tel Aviv University, Schneider Children's Medical Center, Jena University Hospital, Sheba Medical Center, University of Milano-Bicocca, Medizinische Hochschule Hannover
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405043445